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Abstract
Background: The most appropriate treatment for men with prostate cancer and positive pelvic nodes, N+, is an area
of active controversy. We report our 5-years outcomes in men with locally advanced prostate cancer (T1-T4N0-N1M0)
treated with definitive radiotherapy encompassing the prostate and pelvic lymph nodes (intensity modulated
radiotherapy, IMRT) and long-term androgen deprivation therapy (ADT).
Material and methods: Of the 138 consecutive eligible men all living patients have been followed up to almost
5 years. Survival endpoints for 5-year biochemical failure-free survival (BFFS), relapse-free survival (RFS), prostate cancer-
specific survival (PCSS), and overall survival (OS) were assessed by Kaplan-Meier analysis. Univariate and multivariate Cox
regression proportional hazards models were constructed for all survival endpoints. The RTOG morbidity grading system
for physician rated toxicity was applied.
Results: Patients with locally advanced T3-T4 tumors (35 %) and N1 (51 %) have favorable outcome when long-term
ADT is combined with definitive radiotherapy encompassing pelvic lymph nodes. The 5-year BFFS, RFS, PCSS and OS
were 71.4, 76.2, 94.5 and 89.0 %, respectively. High Gleason sum (9–10) had a strong independent prognostic impact on
BFFS, RFS and OS (p = 0.001, <0.001, and 0.005 respectively). The duration of ADT (= > 28 months) showed a significant
independent association with improved PCSS (p = 0.02) and OS (p = 0.001). Lymph node involvement was not associated
with survival endpoints in the multivariate analysis. The radiotherapy induced toxicity seen in our study population was
moderate with rare Grade 3 GI side effects and up to 11 % for Grade 3 GU consisting mainly of urgency and frequency.
Conclusion: Pelvic IMRT in combination with long-term ADT can achieve long-lasting disease control in men with N+
disease and unfavorable prognostic factors.
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Introduction
Optimal treatment of locally advanced and lymph node-
positive (cN1 or pN1) adenocarcinoma of the prostate
has not yet been determined. There is abundant evi-
dence gained from phase III studies that a substantial
number of patients with locally advanced prostate cancer
(PCa) derive a survival benefit from the combination of
radiation and hormonal therapy [1–4]. Randomized trials
of elective nodal irradiation of the pelvic lymph nodes in
N0 men have not been shown to confer a survival benefit
in similar patients [5, 6]. Therefore, the most appropriate
treatment for men with clinically positive pelvic nodes,
cN1 (or cN+), is an area of active controversy. The experi-
ence from extended lymphadenectomy suggests that for a
subgroup of patients with limited positive pelvic lymph
nodes, pN1, irradiation of the pelvic lymphatic structures
could translate into long-lasting disease control [7, 8].
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Similarly, there is emerging retrospective and prospect-
ive data that definitive radiation therapy and androgen
deprivation therapy (ADT) in cN+ may be more benefi-
cial than ADT alone [9–14].
In the present study we investigated the 5-year out-
comes of patients with locally advanced and/or with N+
prostate cancer undergoing intensity modulated radio-




This study concerns consecutively treated patients
treated with IMRT (n = 138) to the prostate, seminal ves-
icles and pelvic nodal basins and/or clinical positive
nodal disease who had at least a 5-years of follow-up.
Two patients were excluded from the survival analyses
due to missing lymph node status. Only patients with
less than 3 positive lymph nodes were eligible. The
protocol was approved by the Ethics Committee of the
Health Region South/East of Norway. All patients gave
written consent.
Nodal sampling and N+ criteria
In addition to the anatomical grading using the TNM/
UICC stage classification [15], the inclusion criteria
were: age < 75 years, no previous invasive cancer, initial
PCa diagnosis made during the last 6 months, pN +M0
or a calculated N+ risk = > 15 % using the Memorial
Sloan-Kettering Cancer Center nomogram [16] and
prognostic high-risk disease defined by D’Amico’s classi-
fication [17]. During the recruitment period from 2004
to 2010 a trend towards radiographic N-assessment by
magnetic resonance imaging (MRI) was seen due to low
yield in the dissected lymph nodes obtained mainly from
the obturator region when applying standard lymphade-
nectomy [18].
IMRT planning and delivery
The delineation of the clinical target volume (CTV) and
organs at risk has been described in detail previously
[19]. Briefly, the CTV for the pelvic nodes was delin-
eated by contouring a 0.7 cm radial area around the pel-
vic iliac vessels and adding a 2 mm margin to obtain a
planning target volume (PTV). The medial portion of
the presacral nodal area was left out in the delineation
of lymph nodes, aiming to spare the recto-sigmoid,
otherwise the contouring was per the recommendations
attainable by the Radiation Therapy Oncology Group
Web site (www.rtog.org).
The rectum was contoured from the anus to the recto-
sigmoid flexure. In the approved IMRT protocol prede-
fined protocol-stated dose constraints to the OARs were
mandatory. The use of 3D-conformal radiation therapy
(CRT) and IMRT in prostate cancer permits dose escal-
ation strategies with improved sparing of normal tissue.
The inverse planning software in Oncentra Masterplan
(Nucletron, Veenendal, The Netherlands) was applied
during the pilot phase of the study, and after 2006 the
inverse planning software Konrad obtained from MRC
Systems (MRC Systems GmbH, Heidelberg, Germany)
was applied. Treatment plans were generated by seven
coplanar fields to the delineated pelvic structures up to a
total dose of 50 Gy encompassing the prostate, seminal
vesicles and nodal basins (target volumes; PTV) by use
of 15-MV photon beams. Radiation to the boost volume
(24 Gy to the seminal vesicles and the prostate for T3b;
24 Gy to the prostate alone for ≤ T3a) was done by a
four-field box technique. No attempt for dose escalation
to N+ patients was included in this protocol. Patients
were instructed to empty the rectum and keep the blad-
der filled during the course of radiotherapy. In the opti-
mized plan the prescribed radiation dose was set equal
to the mean dose of the ITV according to the Inter-
national Commision on Radiation Units and Measure-
ments Reports 62 (ICRU Report 62, www.icru.org).
Image guided patient set-up and irradiation was per-
formed by daily field matching on bony landmarks for
the majority of patients and on three implanted fiducial
markers (Goldlock III, BeamPoint AB, Stockholm,
Sweden) in 30 patients.
Androgen deprivation therapy (ADT)
All patients started neo-adjuvant ADT 6 months prior
to IMRT, and this treatment was continued to a max-
imum of 2.5 years in some patients with pN+ and a
very high-risk profile (Table 1). We applied a 3-months
depot injection with gosereline (Zoladex® 10.8 mg sc).
As prophylaxis against flare-ups, bicalutamide 50 mg ×
1 orally was given for 30 days, beginning 1 week prior
to first injection of gosereline.
Survivorship procedure
Patients were regularly seen in the outpatient clinic at
3–4 month intervals the first 2 years, and then every
6 months for the next 3 years. Routine history and phys-
ical exam was performed including blood samples with
PSA and testosterone.
Physician-rated toxicity at 36 months
Consecutively reported side effects or dysfunction on
erectile potency, urinary, and bowel function were rated
by one physician (WL) at regular intervals during follow-
up. Grading of gastrointestinal and kidney-bladder side
effects was done by the International Toxicity/RTOG
morbidity grading scale [20] Patients’ self-rating side ef-
fects have been published previously [21], but here we
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only report the prevalence of Grade 2 or more toxicity ob-
served during the study period.
Statistical analysis
Primary endpoints of our study included biochemical
failure-free survival (BFFS), relapse-free survival (RFS),
prostate cancer-specific survival (PCSS), and overall
survival (OS). Biochemical failure was defined in
accordance with the Radiation Therapy Oncology
Group – Association of Therapeutic Radiation Oncol-
ogy (RTOG-ASTRO) Phoenix Consensus Conference
definition. Relapse-free survival included local-regional
or distant recurrence, as diagnosed by clinical exam,
imaging, and/or biopsy. Death due to prostate cancer
was defined as death in a patient with a documented
history of hormone-refractory metastatic prostate can-
cer, evidence of a rising PSA at last follow-up visit, and
no other obvious cause of death. Additionally, death
certificates were cross-referenced to confirm cause of
death. Patients who were alive were censored at last
follow-up. For the purpose of calculating BFFS, patients
without biochemical failure were censored at time of
last PSA measurement. Survival endpoints were mea-
sured from the first day of initiation of ADT.
Differences in patient and treatment characteristics
were compared between patients with and without
radiologic and/or pathologic lymph node involvement
using the χ2 test. Thresholds for categorical variables
were defined in accordance with the literature. Univari-
ate and multivariable Cox proportional hazards models
were constructed for all survival endpoints. Hazard ra-
tios for the associations between potential prognostic
factors and survival endpoints were analyzed. Multivari-
able models adjusted for age at diagnosis, pre-treatment
PSA, biopsy Gleason score, clinical stage, lymph node
involvement, and duration of administration of ADT.
Duration of ADT was calculated as the difference be-
tween the start and end dates of ADT administration,
except when patients experienced biochemical failure,
clinical recurrence, or death prior to completion of the
originally prescribed course of ADT. In these cases, dur-
ation of ADT was calculated as the difference between
the event date and start date of ADT. For each survival
endpoint, backwards elimination was used to identify
which covariates to include in the final multivariable
Table 1 Demographic, disease, and treatment characteristics
Characteristic Lymph node positive (n = 58) Lymph node negative (n = 78) P-value
Median age at diagnosis (range), yrs 66.7 (50.9 – 76.8) 67.4 (48.3 – 79.1) 0.03
Mode of detection, n (%) 0.17
Symptomatic 25 (43) 25 (32)
Screening 33 (57) 53 (68)
Median PSA (range), ng/mL 24.4 (1.8 – 109.0) 26.0 (2.9 – 109.0) 0.26
Gleason sum, n (%) 0.21
3 + 3 3 (5) 1 (1)
3 + 4 10 (17) 8 (10)
4 + 3 13 (22) 22 (28)
4 + 4 23 (40) 29 (37)
4 + 5 5 (9) 16 (21)
5 + 4 3 (5) 2 (3)
5 + 5 1 (2) 0 (0)
Clinical stage, n (%) 0.58
T1b 1 (2) 0 (0)
T1c 1 (2) 6 (8)
T2a 3 (3) 1 (1)
T2b 3 (5) 4 (5)
T2c 3 (5) 3 (4)
T3a 23 (40) 32 (41)
T3b 23 (40) 30 (38)
T4 1 (2) 2 (3)
Median duration of ADT (range), months 40.3 (11.9 – 54.4) 28.7 (9.0 – 60.2) <0.001
Abbreviations: prostate-specific antigen (PSA)
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model, using a threshold of P-value of 0.25 to make this
determination. Additionally, Kaplan-Meier survival curves
were constructed for all survival endpoints, with stratifica-
tion by lymph node status and comparison of patient sub-
sets using the log-rank test. Survival estimates at specific
time points were derived from life tables.
Throughout the analysis, two-sided significance testing
was used, and a P-value of 0.05 was considered statisti-
cally significant. All statistical analyses were performed
with Stata software (Stata/IC10.0).
Results
Demographic, tumor, and treatment characteristics are
detailed in Table 1. The proportion of men with at least
one high-risk factor (T3a or PSA >20 ng/mL or Gleason
8–10) or T3b-T4, Gleason grade 5 or two or more risk
factors (very high-risk) were 25 and 75 %, respectively.
Radiologic and/or pathologic lymph node evaluation was
positive for 71 patients (51 %). Men with lymph node in-
volvement were younger and more likely to receive a
duration of ADT that was greater than 28 months, as
compared to men without lymph node involvement
(both p < 0.05). Mode of detection, initial PSA level,
Gleason score, and clinical stage did not differ based on
lymph node status.
Median follow-up of this cohort was 4.9 years (range:
0.9–11.1 years). Of the 136 men in the cohort who
underwent combination treatment, 40 patients (29 %)
experienced biochemical failure during the study period,
and 34 patients (25 %) developed clinical relapse, includ-
ing 15 patients (11 %) with distant metastases, 15 pa-
tients (11 %) with local-regional disease, and 4 patients
(3 %) with concurrent distant and local-regional disease
at time of relapse. In total, 18 patients (15 %) died dur-
ing the follow-up period, including 8 patients (6 %) who
died due to prostate cancer and 10 patients (7 %) who
died from other causes.
For the entire cohort, the 5-year BFFS and 5-year RFS
were 71.4 and 76.2 % respectively. The 5-year PCSS and
5-year OS were 94.5 and 89.0 % respectively (Fig. 1).
Figure 2 displays Kaplan-Meier estimates for survival
endpoints, stratified by the presence of lymph node
involvement. Men with lymph node positive disease
experienced similar 5-year BFFS (p = 0.08), 5-year RFS
(p = 0.07), and 5-year PCSS (p = 0.66), to those without
pelvic nodal involvement. Interestingly, men with lymph
node involvement experienced improved 5-year OS, as
compared to men without lymph node involvement
(96.5 % vs. 78.3 %, p = 0.03).
On univariate analysis, a higher Gleason score was
associated with inferior BFFS (p = 0.001) and inferior
RFS (p = 0.001), but was not associated with either
PCSS or OS (Additional file 1: Table S1). Additionally,
a higher clinical stage was associated with inferior BFFS
(p = 0.03) and inferior RFS (p = 0.05), but not with PCSS
or OS. Interestingly, while lymph node involvement
was not associated with BFFS, RFS or PCSS, it was as-
sociated with improved OS (p = 0.03). A duration of
ADT greater than 28 months was also associated with
improved PCSS (p = 0.03) and improved OS (p < 0.001)
on univariate analysis.
Table 2 details adjusted hazard ratios for the covariates
included in the multivariable model, displaying results
for covariates with a p-value of ≤0.10. A Gleason sum of
9 or 10 was associated with inferior BFFS (p = 0.001),
RFS (p < 0.001), and OS (p = 0.005), and had a borderline
statistically significant association with PCSS (p = 0.07).
Additionally, a duration of ADT greater than 28 months
had a statistically significant association with improved
PCSS (p = 0.02) and improved OS (p = 0.001). Lymph
node involvement was not associated with any of the
survival endpoints on multivariate analysis.
Maximum genitourinary and gastrointestinal toxicities
are shown in Table 3. During the follow-up period, urinary
frequency and urinary urgency were the most common
grade 2 or higher genitourinary toxicities experienced by
patients, with 10 % of patients experiencing grade 3 fre-
quency and 11 % of patients experiencing grade 3 urgency.
The most common grade 2 gastrointestinal toxicities were
fecal urgency and blood in the stool, but grade 3 gastro-
intestinal toxicities were rare overall.
Discussion
In our study of locally advanced and N+ men with pros-
tate cancer, we found a low risk for prostate-specific
mortality (<6 %) during a median of 4.9-years of follow-
up, but moderate biochemical and/or clinical relapse
with combined treatment of pelvic IMRT and ADT for
the entire cohort. This agrees with the efficacy of com-
bination treatment as shown in pivotal phase III trials
for locally advanced PCa [1–4].
Our results in a cohort where 51 % of men were N+
are very favorable at 5 years when compared to the
aforementioned phase III trials for locally advanced, but
predominantly N0 PCa, On multivariable analysis, we
did not find nodal involvement to be prognostic. Fur-
thermore, in our cohort we found an interesting obser-
vation whereby men with N+ had an improved overall
survival compared to patients without lymph node in-
volvement. In the latter, duration of ADT was an inde-
pendent predictor for survival. We did identify Gleason
sum of 9–10 as a universally independent poor prog-
nostic factor for all our clinical endpoints. However,
long-term duration of ADT, greater than 28 months,
was found to be an independent favorable prognostic
factor for PSCC and OS. This last finding is in agree-
ment with level 1 evidence from several randomized
trials [1, 3, 4, 22] that long-term/life-long ADT should
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be applied in men with locally advanced PCa who are
treated with radiotherapy.
Until recently, N+ has been synonymous with M1 dis-
ease, with most men being treated routinely with indefinite
ADT alone and no local therapy. However, patients with
M1 disease have a deleterious 5 year relative survival of
35 % underpinned by the latest report of the Norwegian
Cancer Registry (www.kreftregisteret.no). All of the pro-
spective radiotherapy trials that recruited men with locally
advanced PCa involved none or a minority of N+ patients
(<5 %). Recently population based studies have suggested
that the addition of local therapy in the N1 setting can have
profound effects on survival [13, 14, 23]. Specifically, the
addition of radiation to cN1 patients has suggested these
patients may enjoy long-term disease control [24]. How-
ever, the optimal duration of ADT in men with N1 disease
who receive combined radiotherapy and ADT is unknown.
Longer-term ADT, but not indefinite ADT, was able to
overcome the prognostic significance of N+ status in our
cohort (Table 3). Our data suggests that indefinite ADT
may not be needed for limited N1 patients when combined
with radiotherapy. In addition, dose escalation exceeding
50 Gy to cN1 pelvic lymph nodes not approached in our
protocol may translate in long-lasting disease control.
Our study population consists of patients with aggres-
sive tumors. Micrometastatic disease at diagnosis not de-
tected by today’s staging methods in these patients could
have been associated with early relapse [25]. However,
rare detection of disseminated tumor cells in the bone
marrow (data not shown) and limiting eligibility to < 3
positive LNs supports our assumption that patients in-
cluded in this study were not out of range for curatively
intended treatment. Moreover, in these patients a major
aim is to achieve local control by eradication of the pri-
mary tumor with combined treatment and thereby pre-
venting re-seeding of tumor cells [26].
Involving additional pelvic structures into the prostate
irradiation fields increases the possibility for toxicity.
The prevalence of grade 2 to 3 GI and or GU toxicity
was moderate and mainly related to urgency. The rare
Fig. 1 Kaplan-Meier survival estimates for a biochemical failure-free survival, b relapse-free survival, c prostate cancer-specific survival, and d over-
all survival for overall cohort
Lilleby et al. Radiation Oncology  (2015) 10:232 Page 5 of 8
Fig. 2 Kaplan-Meier survival estimates for a biochemical failure-free survival, b relapse-free survival, c prostate cancer-specific survival, and d overall
survival, stratified by lymph node status. Red curves represent men with radiologic and/or pathologic lymph node involvement. Blue curves represent
men without lymph node involvement
Table 2 Multivariate Cox proportional hazards analysis for associations between covariates and survival endpoints
Covariate Hazard ratio (95 % confidence interval) P-value
Biochemical failure-free survival
Gleason sum 9 or 10 3.33 (1.62 – 6.85) 0.001
Clinical stage T3b/T4 2.17 (1.11 – 4.22) 0.02
Relapse-free survival
Gleason sum 9 or 10 4.43 (2.14 – 9.14) <0.001
Prostate cancer-specific survival
Gleason sum 9 or 10 4.13 (0.87 – 19.58) 0.07
Duration of ADT ≥28 months 0.20 (0.05 – 0.81) 0.02
Overall survival
Age ≥65 years 3.57 (1.00 – 12.82) 0.05
Gleason 4 + 3 17.26 (1.11 – 268.69) 0.04
Gleason 4 + 4 14.67 (1.07 – 200.81) 0.04
Gleason sum 9 or 10 70.11 (3.49 – 1407.99) 0.005
Duration of ADT ≥28 months 0.15 (0.05 – 0.44) 0.001
Multivariable models adjusted for age at diagnosis, pre-treatment PSA, biopsy Gleason score, clinical stage, lymph node involvement, and duration of administration of ADT
Abbreviations: androgen deprivation therapy (ADT)
Threshold of p < 0.25 was used to exclude covariates from the final multivariable model, using backwards elimination
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event of grade 3 rectal bleeding might be due to early
referring of patients to laser coagulation or hyperbaric
oxygenation as a coping strategy. Our recently pub-
lished patient self-reported results showed only a mod-
erate increase of GI/GU side-effects not affecting
overall QoL [19, 21]. Many of the men on this trial
where treated before strict measures for daily image
guidance were institutionalized, such as the use of fi-
ducial markers in combination with Cone-Beam-CT.
Such a patient set-up verification procedure allows a
reduction of the treatment margins related to organ
motion and set-up uncertainties, and a reduction in
toxicity can thereby be expected. In addition, strategies
addressing systemic treatments with a lower toxicity
profile such as therapeutic cancer vaccines or novel
class of androgen receptor inhibitors substituting
partly ADT should be investigated [27, 28].
Strengths and limitations
Our study limitations include retrospective analyses
and the lack of randomization. Still, the similar work-
up regimen and homogeneous treatment applications
in this cohort of men with locally advanced PCa and/
or N1 disease generated some interesting findings
which are clinically meaningful in the wake of future
results from randomized trials in this risk group.
Conclusion
Men with locally advanced and/or N1 prostate cancer
have favorable outcomes following combined radiation
and ADT and this can be achieved with low levels of
toxicity when using IMRT to pelvic structures.
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